Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression-Reference-Cited by-同舟云学术

Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression

Published:2020-04 Issue:2 Volume:72 Page:
ISSN:0393-2249
Container-title:Minerva Urologica e Nefrologica
language:
Short-container-title:Minerva Urol Nefrol

Author:

Palermo Giuseppe,Bassi Pierfrancesco,Racioppi Marco,Recupero Salvatore M.,Sacco Emilio,Campetella Marco,Canu Giulia,Pinto Francesco

Publisher

Edizioni Minerva Medica

Subject

Urology,Nephrology

Link

https://www.minervamedica.it/pdf.php?cod=R19Y2020N02A0214

Reference30 articles.

1. Cancer statistics, 1999

2. U.S. Preventive Services Task Force. Screening for prostate cancer: draft recommendation statement; 2011 [Internet]. Available from: www.uspreventiveservicestaskforce.org/draftrec3.htm [cited 2020, Feb 19].

3. Department of Health and Human Services. ASPE issue brief - overview of the uninsured in the United States: a summary of the 2011 current population survey; 2011 [Internet]. available from: http://aspe.hhs.gov/health/ [cited 2020, Feb 19].

4. The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer

5. Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular biomarkers in prostate cancer tumorigenesis and clinical relevance;Critical Reviews in Oncology/Hematology;2024-02

2. Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society;Minerva Urology and Nephrology;2022-09

3. miR ‐2392 functions as tumour suppressor and inhibits malignant progression of hepatocellular carcinoma via directly targeting JAG2;Liver International;2022-05-11

4. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide;Minerva Urology and Nephrology;2022-02

5. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide;Minerva Urology and Nephrology;2022-02